Close Menu

hepatitis

People in the News: Robert Gish

Premium

Arrowhead Research has appointed Robert Gish as the chairman of its newly created hepatitis B clinical advisory board.

Arrowhead Research last week released new preclinical data on its lead drug candidate, the hepatitis B virus treatment ARC-520, reporting that the agent could trigger up to multi-log reductions in the levels of circulating viral antigens, while lowering levels of the virus' repli

Australian expressed RNAi drug developer Benitec this week provided an update to its pipeline, disclosing that it once again expects to have a candidate in phase I testing next year following its recent acquisition of Tacere Therapeutics.

A Cepheid executive today provided investors with an update on the company's molecular diagnostic pipeline, stating that the firm currently has 14 tests in development for its automated GeneXpert platform and that it expects to offer the broadest test menu of any molecular diagno

Expressed RNAi drug developer Benitec Biopharma this week provided an update on its pipeline, stating that its two lead programs in cancer-associated neuropathic pain and drug-resistant lung cancer have fallen behind schedule as the company further optimizes its therapeutic candi

Arrowhead Research said this week that it has begun the final processes required to file an investigational new drug application for its RNAi-based hepatitis B treatment ARC-520, including manufacturing, toxicology studies, and preparation of a pre-IND data package for submission

NEW YORK (GenomeWeb News) – A pair of studies in the early, online version of Nature Genetics are highlighting the types of genetic mutations that underlie the liver cancer hepatocellular carcinoma, including forms of the disease related to hepatitis B and hepatitis C virus infection.

Just months after adding a hepatitis B treatment to its pipeline, Arrowhead Research's top official this week said that the company expects the program to yield an investigational new drug application in the first half of next year.

By Doug Macron
Benitec Biopharma last week broke out new details about its in-house pipeline, stating that it aims to have three drugs in clinical studies next year and possibly a fourth by 2014.

Arrowhead Research this week released a white paper detailing the market potential for a hepatitis B therapy and the use of its dynamic polyconjugate siRNA-delivery technology to attack the virus.

Pages

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.